Physician profile
Ariy Volfson
NPI 1306008446
$3,056.49
in general payments reported to CMS, 2019-2025
24 companies · $241 in 2025
The $241 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $194 · 2021: $397 · 2022: $443 · 2023: $767 · 2024: $810 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,819.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $526.28 | 2019-2025 | Creon, Linzess, Skyrizi |
| Qol Medical, LLC | $490.50 | 2021-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.19 | 2020-2023 | Trulance, Xifaxan, Plenvu |
| Redhill Biopharma INC. | $244.45 | 2020-2023 | Talicia |
| Ardelyx, INC. | $196.29 | 2022-2025 | Ibsrela |
| Celgene Corporation | $173.08 | 2021-2023 | Zeposia |
| Braintree Laboratories, INC. | $167.87 | 2020-2023 | Sutab |
| Medical Device Business Services, INC. | $146.58 | 2024 | Linx Reflux Management System |
| Genzyme Corporation | $139.97 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.76 | 2019-2025 | Entyvio |
| Ironwood Pharmaceuticals, INC | $121.00 | 2021-2024 | Linzess |
| Pfizer INC. | $115.01 | 2019-2024 | |
| Glaxosmithkline, LLC. | $78.58 | 2019-2020 | |
| Janssen Biotech, INC. | $55.96 | 2019-2024 | Stelara, Tremfya |
| Intercept Pharmaceuticals, INC. | $47.41 | 2020-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $41.46 | 2021-2022 | |
| Davol INC. | $35.64 | 2025 | Phasix Mesh |
| Madrigal Pharmaceuticals | $18.55 | 2025 | Rezdiffra |
| Lilly USA, LLC | $16.97 | 2024 | Omvoh |
| Ferring Pharmaceuticals INC. | $14.67 | 2024 | Rebyota |
| Gilead Sciences, INC. | $14.34 | 2021 | |
| Laborie Medical Technologies Corp. | $14.07 | 2024 | Alphaone |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.71 | 2023 | Cyltezo |
| Shionogi INC | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariy Volfson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.